Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Distler

Showing results (561-570 of 622) with videos related to

Pageof 63
Sort By:
The European Respiratory Journal|September 4, 2025
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)Katerina M Antoniou, Oliver Distler, Ana-Maria Gheorghiu, et al.
Annals of the Rheumatic Diseases|September 5, 2025
ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung diseaseKaterina M Antoniou, Oliver Distler, Ana-Maria Gheorghiu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
International Journal of Rheumatic Diseases|October 10, 2025
Discordance in Patient and Physician's Perception of Disease Activity Among Idiopathic Inflammatory Myopathy Patients: Insights From the COVAD StudyRudra P Goswami, Parikshit Sen, Zoha Zahid Fazal, et al.
The European Respiratory Journal|October 22, 2021
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryMarius M Hoeper, Christine Pausch, Ekkehard Grünig, et al.
Journal of Clinical Epidemiology|April 12, 2014
Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteriaSindhu R Johnson, Raymond P Naden, Jaap Fransen, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Nature|February 1, 2019
PU.1 controls fibroblast polarization and tissue fibrosisThomas Wohlfahrt, Simon Rauber, Steffen Uebe, et al.
Rheumatology (Oxford, England)|February 13, 2021
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohortMaria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 17, 2022
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysisMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
Pageof 63

Showing results (561-570 of 622) with videos related to

Sort By:
Pageof 63
The European Respiratory Journal|September 4, 2025
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)Katerina M Antoniou, Oliver Distler, Ana-Maria Gheorghiu, et al.
Annals of the Rheumatic Diseases|September 5, 2025
ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung diseaseKaterina M Antoniou, Oliver Distler, Ana-Maria Gheorghiu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
International Journal of Rheumatic Diseases|October 10, 2025
Discordance in Patient and Physician's Perception of Disease Activity Among Idiopathic Inflammatory Myopathy Patients: Insights From the COVAD StudyRudra P Goswami, Parikshit Sen, Zoha Zahid Fazal, et al.
The European Respiratory Journal|October 22, 2021
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryMarius M Hoeper, Christine Pausch, Ekkehard Grünig, et al.
Journal of Clinical Epidemiology|April 12, 2014
Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteriaSindhu R Johnson, Raymond P Naden, Jaap Fransen, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Nature|February 1, 2019
PU.1 controls fibroblast polarization and tissue fibrosisThomas Wohlfahrt, Simon Rauber, Steffen Uebe, et al.
Rheumatology (Oxford, England)|February 13, 2021
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohortMaria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 17, 2022
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysisMarius M Hoeper, Christine Pausch, Karen M Olsson, et al.
Pageof 63